Recent

% | $
Quotes you view appear here for quick access.

Sequenom Inc. Message Board

  • phenomenology phenomenology Jun 8, 2010 1:59 PM Flag

    Barrrons Today.. if you haven't seen it

    This is a tentative upgrade from neutral to neutral.. note last rating. They are cautious about Dr.'s acceptance. I don't think Dr.'s follow the stock market and make up their mind because of Dragon lady.. they make up their mind on published results so if Lo is hot, then its off to the races.


    JUNE 8, 2010, 11:47 AM ET
    Sequenom: Down’s Test Data in Mid-July?

    Shares of biotech Sequenom (SQNM) are off 4 cents, or 0.7%, at $5.69, as Ladenburg Thalman’s Kevin DeGeeter this morning wrote that July 11 may be the date for an important disclosure of trial results in the development of the company’s non-invasive prenatal test for Down’s Syndrome.

    DeGeeter notes that Dr. Dennis Lo, the company’s scientific advisor on the test, is scheduled to give a talk at the International Society for Prenatal Diagnosis on July 11, entitled “DNA or RNA: Which is better for noninvasive diagnosis of aneuploidy” on July 13 at the conference. He thinks the timing is consistent with what Sequenom has said about the timing for the release of further test results this summer.

    Lo’s paper, if it is indeed the relevant data, could demonstrate the Down’s test’s sensitivity to a high degree, at perhaps 95% or greater depending on the sample size.

    DeGeeter maintains a “Neutral” rating on the shares, writing that there are “structural and economic challenges in displacing Quad test” for Down’s, and that he’s concerned about Sequenom management’s ability to regain physician trust after positive results for the test were compromised last year by tampering with lab data.

    Previously: Sequenom: Ladenberg Starts at Neutral; Pre-Natal Testing Unattractive, April 27, 2010.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Unfortunately, Lo's test performance has absolutely no bearing on the test SQNM is trying to validate in the SCMM. Under CLIA and CAP the SCMM test is considered a "home brew" or laboratory-developed test with its own performance characteristics. They are not allowed by law to claim the performance of someone else's test (Lo's) is the same as theirs.

      That is why SCMM has to perform their own validation and SQNM can't even pretend to claim their test performs the same.

    • Price target?

      • 1 Reply to nostradonuts
      • if there is no upgrade to buy then I guess they think the current price is good enough (i.e 5$-7$).

        I do too.

        a lot of stuff I see out there relate to past events and the whole trick is not to analyze the past (which make you a good financial reporter) but to try and estimate future events based on risk management (which makes you a good investor!).

        SQNM is all about the T21 test (as I strongly believe) but it is also all about the FUTURE!

        the new management team and our CEO are doing a GREAT job and have put in place a VERY comfortable time schedule. one that can easily be breached.

        this cunning CEO is setting the stage for a classic "under promisse and over deliver" kind of situation.

        I know it is hard to accept because the market do not appreciate at the moment the stock according to last relevant events but I it will!

        SQNM will fly to mid 30$ on ANY real news regarding T21 progress.

        A

 
SQNM
2.39+0.01(+0.21%)Aug 26 4:00 PMEDT